In Brief: Contact lens antitrust suit
This article was originally published in The Gray Sheet
Contact lens antitrust suit: Filed by 22 states in Brooklyn District Court Dec. 19 against Johnson & Johnson subsidiary Vistakon, Bausch & Lomb, Ciba Vision Corp., the American Optometric Association and individual optometrists. The suit alleges the defendants violated federal and state antitrust laws by limiting lens sales to licensed eye professionals, thereby restricting competition in the sale of soft contact lenses by not selling to mail-order firms, pharmacies, buying clubs or department stores. CIBA says it is "dismayed" by the allegations in light of a two-year investigation by the State of Florida which the firms says "found no evidence that [it] had violated antitrust laws," and vows to "vigorously defend" itself. Bausch & Lomb also says it will defend its policy...
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.